Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
This study has been completed.
Study NCT00077558 Information provided by National Cancer Institute (NCI)
First Received: February 10, 2004 Last Updated: July 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Preleukemia
Syndrome
More general conditions related to this trial
Bone Marrow Diseases
Disease
Hematologic Diseases
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
fludarabine phosphate
triapine
Additional drug interventions recognized in this trial
Fludarabine
Fludarabine monophosphate
Vidarabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
